The cost of immunotherapy drug Nivolumab has fallen to ₹30,000 per cycle from over ₹1 lakh due to new biosimilar competition. While this improves accessibility for cancer patients, the actual benefit depends on whether hospitals adopt these cost-effective options or continue stocking higher-margin drugs. This shift signals growing competitive pressure in the oncology sector as more biosimilar alternatives enter the market.
Cancer treatment costs in India are seeing a major change as the immunotherapy drug Nivolumab becomes more affordable. Prices have dropped significantly, falling from over ₹1 lakh to roughly ₹30,000 per cycle. This reduction follows the entry of biosimilars—versions of the drug developed to be highly similar to the original biological product, typically offered at a lower cost. This development is driving a sharp rise in prescriptions, as the treatment is becoming accessible to a much broader patient base.
Clinical evidence supports this wider adoption. Data from institutions like the Tata Memorial Centre indicates that Nivolumab is effective across approximately 25 different types of tumors. In some instances, such as certain early-stage colorectal cancers, the use of this immunotherapy can even allow patients to avoid more invasive regimens like chemotherapy or surgery. Survival rates for advanced-stage cases, such as melanoma, have also shown improvement in clinical settings where these checkpoint inhibitors are used.
For the healthcare sector and investors, the next phase is about institutional adoption. Despite the reduction in manufacturer prices, the savings may not fully reach the end user if hospitals continue to prioritize higher-priced original drugs to protect their profit margins. This creates a critical bottleneck, where the pharmacy procurement policy of a healthcare facility often determines whether the patient can actually access the lower-cost version. The challenge lies in whether hospitals will align their purchasing strategies with these more affordable alternatives.
Regulatory authorities are also actively managing drug costs. The National Pharmaceutical Pricing Authority has recently capped trade margins for 137 anti-cancer medications, with an estimated potential annual saving of ₹2,500 crore for patients. This regulatory push is designed to prevent excessive retail pricing. However, the effectiveness of this move still hinges on how hospital purchasing practices evolve to reflect these constraints.
Looking ahead, the competitive landscape is expected to intensify. With four additional biosimilars preparing to enter the Indian market, further downward pressure on pricing is anticipated. Investors may want to monitor how quickly hospitals adopt these cheaper alternatives and whether this rising competition forces a permanent shift in the pricing models used for cancer care in the country.